...
首页> 外文期刊>European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology >Hydrosoluble fiber (Plantago ovata husk) and levodopa II: experimental study of the pharmacokinetic interaction in the presence of carbidopa.
【24h】

Hydrosoluble fiber (Plantago ovata husk) and levodopa II: experimental study of the pharmacokinetic interaction in the presence of carbidopa.

机译:水溶性纤维(车前子壳)和左旋多巴II:在卡比多巴存在下药代动力学相互作用的实验研究。

获取原文
获取原文并翻译 | 示例

摘要

Levodopa combined with carbidopa constitutes one of the most frequent medication in the treatment of Parkinson's disease. Plantago ovata husk (water-soluble fiber) improves levodopa absorption conditions, but when this drug is administered with carbidopa, fiber could reduce its effectiveness. The purpose of this study is to investigate whether the presence of P. ovata husk modifies in rabbits the bioavailability and other pharmacokinetic parameters of levodopa (20 mg/kg) when administered by the oral route with carbidopa (5 mg/kg). We have also studied whether pharmacokinetic modifications are fiber-dose dependent (100 and 400 mg/kg). When levodopa and carbidopa were administered with 100 mg/kg P. ovata husk, the value of AUC for levodopa diminishes 29.7% (sign, n=6, P<0.05) and Cmax 28.1% (sign, n=6, P<0.05) in relation to the values obtained when these drugs were administered without fiber. If the dose of fiber was 400 mg/kg, the decrease was smaller: 20.4% for AUC (no significant difference) and 24.6% for Cmax (sign, n=6, P<0.05), that may indicate an inhibitory action of AADC by the fiber or any of its partial hydrolysis products. On the other hand, since certain time on, levodopa concentrations are always higher in the groups that receive fiber: 210 min with 100 mg/kg and 150 min with 400 mg/kg. The administration of P. ovata husk with levodopa/carbidopa to patients with Parkinson disease could be beneficial and in particular in those patients who also suffer constipation due to an improvement of levodopa kinetic profile with higher final concentrations, a longer plasma half-life and lower Cmax.
机译:左旋多巴联合卡比多巴是治疗帕金森氏病最常见的药物之一。车前子壳(水溶性纤维)改善了左旋多巴的吸收条件,但与卡比多巴一起使用时,纤维会降低其有效性。这项研究的目的是调查通过口服途径与卡比多巴(5 mg / kg)一起施用时,卵白僵菌的存在是否能改善兔体内左旋多巴(20 mg / kg)的生物利用度和其他药代动力学参数。我们还研究了药代动力学修饰是否依赖纤维剂量(100和400 mg / kg)。当左旋多巴和卡比多巴分别以100 mg / kg卵形毕赤酵母果皮施用时,左旋多巴的AUC值减少29.7%(sign,n = 6,P <0.05)和Cmax 28.1%(sign,n = 6,P <0.05 )相对于这些药物不加纤维给药时获得的值。如果纤维剂量为400 mg / kg,则下降幅度较小:AUC为20.4%(无显着性差异),Cmax为24.6%(正负号,n = 6,P <0.05),这可能表明AADC具有抑制作用由纤维或其任何部分水解产物产生。另一方面,从一定时间开始,接受纤维的人群中左旋多巴的浓度始终较高:100 mg / kg时210分钟,400 mg / kg时150分钟。对帕金森氏病患者给予卵白头孢菌素皮和左旋多巴/卡比多巴可能是有益的,特别是在那些由于左旋多巴动力学特性改善,最终浓度更高,血浆半衰期更长和更低而患有便秘的患者中最高

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号